跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
IS-001
首页
药物
IS-001
IS-001
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Methods for treating immunodeficiency disease
US 10610527 B2
申请人: X4 PHARMACEUTICALS INC
优先权: 2015
CN
US
5 件公开
USE OF PCLX-001 OR PCLX-002 AS A RADIOSENSITIZER
EP 4648775 A1
申请人: PACYLEX PHARMACEUTICALS INC
优先权: 2023
CN
EP
US
WO
4 件公开
EPAC1 INHIBITORS FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
EP 4072547 A1
申请人: INST NAT SANTE RECH MED
优先权: 2019
EP
US
WO
4 件公开
ORAL PCLX-001 IN THE TREATMENT OF HUMAN CANCER
EP 4486344 A4
申请人: PACYLEX PHARMACEUTICALS INC
优先权: 2022
CN
EP
US
3 件公开
WO 2025050208 A1
申请人: PACYLEX PHARMACEUTICALS INC
优先权: 2023
WO
THE CO-CULTURE METHOD OF SPHINGOMONAS SP. BACTERIAL STRAIN AND ASPERGILLUS SP. FUNGUS STRAIN, NEW ANTI-CANCER AND ANTIBIOTIC GLIONITRINS DERIVED FROM THIS CO-CULTURE METHOD, AND PHARMACEUTICAL COMPOSITION CONTAINING GLIONITRINS OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS AN ACTIVE INGREDIENT
US 2010215620 A1
申请人: KOREA INST SCI & TECH
优先权: 2007
CN
US
2 件公开
Solid Powder Cosmetic And Method For Producing The Same
US 2012034281 A1
申请人: KANEKO KATSUYUKI
优先权: 2009
EP
US
2 件公开
Methods for treating cancer
US 11357742 B2
申请人: X4 PHARMACEUTICALS INC
优先权: 2015
CN
US
2 件公开
US 11337969 B2
申请人: X4 PHARMACEUTICALS INC
优先权: 2016
CN
US
2 件公开
CN 108883132 A
申请人: X4 PHARMACEUTICALS INC
优先权: 2016
CN
US 10953003 B2
申请人: X4 PHARMACEUTICALS INC
优先权: 2016
US
CN 110996952 A
申请人: X4 PHARMACEUTICALS INC
优先权: 2017
CN
METHOD AND COMPOSITION FOR TREATING CORONA VIRUS, INFLUENZA, AND ACUTE RESPIRATORY DISTRESS SYNDROME
US 20250222024 A1
申请人: REVERSPAH LLC
优先权: 2020
CN
US
2 件公开
USE OF N-MYRISTOYL TRANSFERASE (NMT) INHIBITORS IN THE TREATMENT OF CANCER, AUTOIMMUNE DISORDERS, AND INFLAMMATORY DISORDERS
US 2024350481 A1
申请人: PACYLEX PHARMACEUTICALS INC
优先权: 2020
CN
US
2 件公开
FORMULATIONS AND METHODS FOR TREATING ACUTE CANNABINOID OVERDOSE
EP 4247362 A4
申请人: ANEBULO PHARMACEUTICALS INC
优先权: 2020
EP
US
2 件公开
第 1 / 10 页
上一页
下一页
药物
反馈